These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 21692765

  • 21. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.
    Smorodinsky E, Ansdell DS, Foster ZW, Mazhar SM, Cruite I, Wolfson T, Sugay SB, Iussich G, Shiehmorteza M, Kono Y, Kuo A, Sirlin CB.
    J Magn Reson Imaging; 2015 May; 41(5):1259-67. PubMed ID: 24811860
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.
    Tsushima Y, Kanal E, Thomsen HS.
    Br J Radiol; 2010 Jul; 83(991):590-5. PubMed ID: 20413447
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
    Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J.
    Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
    Abu-Alfa AK.
    Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
    [Abstract] [Full Text] [Related]

  • 31. [Kidney and iodinated and gadolinium-based contrast agents].
    Clément O, Faye N, Fournier L, Siauve N, Frija G.
    J Radiol; 2011 Apr; 92(4):291-8. PubMed ID: 21549885
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
    Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A.
    Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
    [Abstract] [Full Text] [Related]

  • 34. Time-dependent decrement of dermal gadolinium deposits and significant improvement of skin symptoms in a patient with nephrogenic systemic fibrosis after temporary renal failure.
    Schäd SG, Heitland P, Kühn-Velten WN, Gross GE, Jonas L.
    J Cutan Pathol; 2013 Nov; 40(11):935-44. PubMed ID: 24102613
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD, Bernheisel CR.
    Am Fam Physician; 2009 Oct 01; 80(7):711-4. PubMed ID: 19817341
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation.
    Wilford C, Fine JD, Boyd AS, Sanyal S, Abraham JL, Kantrow SM.
    Am J Dermatopathol; 2010 Feb 01; 32(1):71-5. PubMed ID: 19940755
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Large sample of nephrogenic systemic fibrosis cases from a single institution.
    Lee CU, Wood CM, Hesley GK, Leung N, Bridges MD, Lund JT, Lee PU, Pittelkow MR.
    Arch Dermatol; 2009 Oct 01; 145(10):1095-102. PubMed ID: 19841395
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.